Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.

Autor: Fogelman D; The University of Texas MD Anderson Cancer Center, Houston, Texas., Cubillo A; Centro Integral Oncológico Clara Campal, Madrid, Spain., García-Alfonso P; Hospital General Universitario Gregorio Marañón, Madrid, Spain., Mirón MLL; Hospital Universitario Virgen del Rocío, Sevilla, Spain., Nemunaitis J; University of Toledo College of Medicine and Life Sciences, Toledo, Ohio., Flora D; Oncology Hematology Care, Cincinnati, Ohio., Borg C; University Hospital of Besançon, Besançon, France., Mineur L; Institut Sainte Catherine, Avignon, France., Vieitez JM; Hospital Universitario Central de Asturias, Oviedo, Spain., Cohn A; Rocky Mountain Cancer Centers, Denver, Colorado., Saylors G; Charleston Hematology Oncology Associates, Charleston, South Carolina., Assad A; Incyte Corporation, Wilmington, Delaware., Switzky J; Incyte Corporation, Wilmington, Delaware., Zhou L; Incyte Corporation, Wilmington, Delaware., Bendell J; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.

Publikováno v: Cancer medicine [Cancer Med] 2018 Nov; Vol. 7 (11), pp. 5382-5393. Date of Electronic Publication: 2018 Aug 19.